Pediatric Hematological Malignancies: Immunotherapy, Causes of Childhood Haematological Cancers, Clinical Manifestation, Treatment and Problems Occurring After Treatment
Article Sidebar
-
Acute myeloid leukemia, Cancer, Chemotherapy, Children, Cytogenetics, Etiology, Genetic abnormalities, Hematological malignancies
Abstract
Cancers that start in the cells of tissues that produce blood, like bone marrow, are known as haematological malignancies. Despite their rarity, blood malignancies continue to top the list of killers among children ages 1–14. Reducing death rates is possible by early discovery, which improves the likelihood of effective treatment. Among youngsters, leukaemias and lymphomas make up over 50% of all new cancer cases. Despite significant progress—the overall survival rate has increased from 10% to about 90% today—the survival rate is significantly lower for many uncommon malignancies. If the mechanisms and genetic abnormalities involved in leukemogenesis can be better understood, tailored therapy has the potential to increase anti-leukemic efficacy while decreasing treatment-related morbidity or mortality. More than 80% of children survive childhood thanks to improvements in the last several decades. Clinical trials carried out by many research groups, including those specialising in paediatrics and oncology, have contributed to these advancements. These were complemented by the substantial contributions made by the discovery of efficient therapeutic agents when combined with different chemotherapeutic drugs. Cure rates for non-lymphoblastic leukaemia have barely reached 50%, despite the overall survival rate of malignancies improving to 90%. Additionally, stem cell transplantation and other intensified regimens have improved outcomes; yet, contemporary therapies are linked to several acute and late complications, and related consequences seem to be on the rise. Haematological cancers can be better treated and patients can have a better chance of survival if our knowledge of the genes and processes that cause them grows. Advances in molecular biology have greatly enhanced our capacity to detect and prevent illness recurrence, monitor how patients react to various treatment plans, make more accurate predictions about their prognoses, and personalise their treatments. In order to develop effective treatments for subsets of children with haematological malignancies, the paediatric oncology and allied research communities must first identify and confirm the most significant therapeutic targets.
Full text article
References
Noetzli L, Lo RW, Lee-Sherick AB, et al. Germline mutations in ETV6 are associated with thrombocytopenia, red cell macrocytosis and predisposition to lymphoblastic leukemia. Nat Genet. 2015;47(5):535-538.
Mullighan CG, Goorha S, Radtke I, et al. Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature. 2007;446(7137):758-764.
Gu Z, Churchman ML, Roberts KG, et al. PAX5-driven subtypes of B-progenitor acute lymphoblastic leukemia. Nat Genet. 2019;51 (2):296-307.
Churchman ML, Qian M, Te Kronnie G, et al. Germline genetic IKZF1 variation and predisposition to childhood acute lym- phoblastic leukemia. Cancer Cell. 2018;33(5):937-948.
Kuehn HS, Boisson B, Cunningham-Rundles C, et al. Loss of B cells in patients with heterozygous mutations in IKAROS. N Engl J Med. 2016;374(11):1032-1043.
Mullighan CG, Miller CB, Radtke I, et al. BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros. Nature. 2008;453(7191):110-114.
Mullighan CG, Su X, Zhang J, et al. Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. N Engl J Med. 2009;360(5):470- 480.
Zhang J, McCastlain K, Yoshihara H, et al. Deregulation of DUX4 and ERG in acute lymphoblastic leukemia. Nat Genet. 2016;48(12):1481-1489.
Brown AL, Arts P, Carmichael CL, et al. RUNX1-mutated families show phenotype heterogeneity and a somatic mutation pro- file unique to germline predisposed AML. Blood Adv. 2020;4(6):1131-1144.
Feurstein S, Godley LA. Germline ETV6 mutations and predisposition to hematological malignancies. Int J Hematol. 2017;106 (2):189-195.
Gocho Y, Yang JJ. Genetic defects in hematopoietic transcription factors and pre- disposition to acute lymphoblastic leukemia. Blood. 2019;134(10):793-797.
Papaemmanuil E, Hosking FJ, Vijayakrishnan J, et al. Loci on 7p12.2, 10q21.2 and 14q11.2 are associated with risk of childhood acute lymphoblastic leukemia. Nat Genet. 2009;41(9):1006-1010.
Trevino LR, Yang W, French D, et al. Germline genomic variants associated with childhood acute lymphoblastic leukemia. Nat Genet. 2009;41(9):1001-1005.
Perez-Andreu V, Roberts KG, Harvey RC, et al. Inherited GATA3 variants are associated with Ph-like childhood acute lymphoblastic leukemia and risk of relapse. Nat Genet. 2013;45(12):1494-1498.
Qian M, Xu H, Perez-Andreu V, et al. Novel susceptibility variants at the ERG locus for childhood acute lymphoblastic leukemia in Hispanics. Blood. 2019;133(7):724-729.
Qian M, Zhao X, Devidas M, et al. Genome- wide association study of susceptibility loci for T-cell acute lymphoblastic leukemia in children. J Natl Cancer Inst. 2019;111 (12):1350-1357.
de Smith AJ, Lavoie G, Walsh KM, et al. Predisposing germline mutations in high hyperdiploid acute lymphoblastic leukemia in children. Genes Chromosomes Cancer. 2019;58(10):723-730.
Pouliot GP, Degar J, Hinze L, et al. Fanconi- BRCA pathway mutations in childhood T- cell acute lymphoblastic leukemia. PLoS One. 2019;14(11):e0221288.
Winer P, Muskens IS, Walsh KM, et al. Germline variants in predisposition genes in children with Down syndrome and acute lymphoblastic leukemia. Blood Adv. 2020;4(4):672-675.
Greaves M. Pre-natal origins of childhood leukemia. Rev Clin Exp Hematol. 2003;7(3):233-245.
Grulich AE, Vajdic CM, Falster MO, et al. Birth order and risk of non-hodgkin lymphoma—true association or bias? Am J Epidemiol 2010; 172(6): 621-30.
Carozza SE, Li B, Wang Q, Horel S, Cooper S. Agricultural pesticides and risk of childhood cancers. Int J Hyg Environ Health 2009; 212(2): 186-95.
Morton LM, Wang SS, Devesa SS, Hartge P, Weisenburger DD, Linet MS. Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. Blood 2006; 107(1): 265-76.
Li J, Thompson TD, Miller JW, Pollack LA, Stewart SL. Cancer incidence among children and adolescents in the United States, 2001-2003. Pediatrics 2008; 121(6): e1470-7.
Burkhardt B. Paediatric lymphoblastic T-cell leukaemia and lymphoma: one or two diseases? Br J Haematol 2010; 149(5): 653-68.
Bolarinwa RA, Ndakotsu MA, Oyekunle AA, Salawu L, Akinola NO, Durosinmi MA. AIDS-related lymphomas in Nigeria. Braz J Infect Dis 2009; 13(5): 359-61.
Kuriakose P. Targeted therapy for hematologic malignancies. Cancer Contr 2005; 12(2): 82-90.
Caryn E. Sorge, Jenny K. McDaniel and Ana C. Xavier. Targeted Therapies for the Treatment of Pediatric Non-Hodgkin Lymphomas: Present and Future. Pharmaceuticals 2016; 9: 28.
Hudson MM, Mertens AC, Yasui Y, et al. Health status of adult long-term survivors of childhood cancer: a report from the Childhood Cancer Survivor Study. JAMA 2003; 290(12): 1583-92
Gurney JG, Kadan-Lottick NS, Packer RJ, et al. Endocrine and cardiovascular late effects among adult survivors of childhood brain tumors: Childhood Cancer Survivor Study. Cancer 2003; 97(3): 663-73.
Mertens AC, Yasui Y, Neglia JP, et al. Late mortality experience in five-year survivors of childhood and adolescent cancer: the Childhood Cancer Survivor Study. J Clin Oncol 2001; 19(13): 3163-72.
Mertens AC, Yasui Y, Liu Y, et al. Pulmonary complications in survivors of childhood and adolescent cancer. A report from the Childhood Cancer Survivor Study. Cancer 2002; 95(11): 2431-41.
Wallace WH, Blacklay A, Eiser C, et al. Developing strategies for long term follow up of survivors of childhood cancer. BMJ 2001; 323(7307): 271-4.
Authors
Copyright (c) 2025 https://creativecommons.org/licenses/by/4.0/
This work is licensed under a Creative Commons Attribution 4.0 International License.